2020 Nelson's Pediatric Antimicrobial Therapy

The 26th edition provides practical, evidence-based recommendations from the experts in antimicrobial therapy for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help health care providers select the best of all antimicrobial choices.

Drug descriptions cover pediatric-appropriate antimicrobial agents available today and include complete information about dosing regimens.

New in the 26th edition:

• First pediatric approval of beta-lactam/beta-lactamase inhibitor for CRE (carbapenem-resistant enteric bacilli), ceftazidime-avibactam
• Replacement antibiotics for cefotaxime (lack of availability in the US), including ceftriaxone and cefepime (for neonates)
• Situations in which ceftaroline is preferred over vancomycin by the Editors for MRSA infections
• Updates on management of influenza, including baloxavir (now approved for children >12 years)
• New approaches to treatment of mucomycosis
• New recommendations for malaria
• More than 150 new references!